NASDAQ sight on Friday showed almost as many institutional declines as buyers. Dr. Kim has to attract some BP validation and support for our platform. Good Post FDA.
Fda, do you know how many times I have brought this very subject up here? You are talking to a herd of Dr. Kim worshipers who can't see the business end this company. The are a nickle and dime crowd that scream, go it alone, more money for us, and miss the big picture. ADXS has a great management team that is doing what we should be doing. We have some of the best talent in the field and they are coming to work for INO because we have something special. We are falling short in the business end by not focusing on our "low hanging fruit" and bringing a plethora of offerings to the market. Without BP support, this road is a dangerous one for a small bio like INO. Constant dilution is not a good thing. NASDAQ
As accurate a post as I have seen here. We had the momentum and launched our low hanging fruit vaccine only to have a P2 less than stellar. Now we take a year and a half off waiting for a Peer Review that will mean little before we start a P3 while the competition races ahead of us on the same cancer getting orphan status. Do you think big pharma isn't looking? Dilution after dilution and we fall behind the competition with lots of cash in our pockets. Go figure. First to market with an approved vaccine seems like they dominate the market even if we eventually get there. Looks to me like Three or Four years before we can compete in the same arena. Poor execution and planing.
I agree bourbon, but i also feel that the number of dilutions in the narrow time frame we have experienced without partnerships is also as big a factor to. The P2 results caused a three week downtrend that cost Dr. Kim 2.5M of his own money just to halt the fall and try to establish a floor. Noble, but temporary. I have all the respect for his Wharton education as there are two in our family and I know their value, but Dr. Kim's execution is leaving me at a loss. I have enjoyed investing in much better run Bio's and thought this one had all the elements I look for, but I have to say at this point, I am concerned about execution and finance.
Well said Alex, I completely agree. Not only that but it pushes out the time frame for going to market. When you are talking in terms of years these costly mistakes get costlier every day, and that is a huge problem. We have given up a lot of our competitive advantage for sure.
Reading this thread and your opinions, I have to say you guys hit it straight on. Last year we had the momentum and Dr. Kim blew it with the verbiage and raised shareholder expectations. I can tell you that big pharma and key investors have zeroed in on ADXS and that is boosting the pps and the validation we had with Roche. Don't ask me how I know, I do. They are in the drivers seat right now going straight to P2 on some indications with FDA approval and already have secured Orphan status with some still in trials. This company has the management that is making it happen both clinically and financially. The bigs have this one pegged to go up sharply and I sold INCY last year for INO after watching Dr. Kim deliver interviews, my mistake so far.
As far as Listeria vector is concerned, it is getting the job done with data they are loving. We had the mojo last year and we let it slip away. Now it is up to management here to impress the street with what we have with new data. I will say Dr. Kim looks to be all over the place and not focused as was stated above. I think that is the impression others looking at INO are getting as well and why we can't seem to interest big pharma at this point. Still love the theories and the platform, so I will wait for further confirmation.
I've read carefully everything you have ever written Mirro, but what are you smoking tonight? I would be satisfied if good old Alec accomplished any one of those items. I have waited as long as you and love the tech, in spite of the lackluster management, but what makes you think they have grown up all at once?
I was just wondering how much the patents have increased in value over the past six months with all that has been revealed? And nobody is recognizing it yet. But when they do it should be a blast.
I thought so. Point being that fast track would allow them to front load results long before we get to play in the same arena. That is big as I see it.
Don't know bourbon. Been looking hard at Adxs recently as they seem to have the mojo and some big interest. Checked our home page and see all the trials listed and late starts and no data flowing, we seem to be playing catch up. So many dilutions is a short time frame and little data. Everything seems scattershot to me as if we are throwing tons of cash at the trials, on our own, with only government hand outs. The recent 250m bomb followed by the partner agreement with ourselves has me wondering what he is doing. Gonna catch a ton of krap for this I'm sure, but I am looking hard at our competition and why they are so locked up with big pharma. Trying to see if I just gave Dr. Kim too much credit. Big pharma adds so much validation and cash, it's hard to ignore.
Yeah, a lot of us feel that way, but you know Tokman. Very little in the way of investor help.
What is wrong with wanting more evidence? Didn't Dr. Kim have center stage with all of his quotes last year and raise expectations for all investors? He Dwarfed our shares and has diluted four times in a year. Even though the 250 registration is still out there, Wall St. wants to justify their investment here with facts in the form of data and P2 didn't do it. The momentum was ours and he lost it with Roche and waiting for Peer Review. I would like to hear him and his colleagues gives something new besides partnering with ourselves. I had the patience for INCY and it was a good ride and hold here for another, but what I see is blown opportunity to boost our awareness. I have no problem with Wall St. wanting more. They are slowly coming around but would be a lot quicker with data and partnership PR.